This study was performed to elucidate the pharmacokinetic profiles of antimycobacterial regimens for peritoneal dialysis patients.
♦ Patients
Nine patients on maintenance continuous ambulatory peritoneal dialysis (CAPD) were included in this study.
♦ Methods
After administering a conventional oral dose of antituberculosis medications, we measured plasma and peritoneal fluid concentrations of isoniazid by fluorometry, and rifampin and pyrazinamide by high performance liquid chromatography. The assay data were subjected to pharmacokinetic analysis.
♦ Results
Average peak plasma concentrations of isoniazid, rifampin, and pyrazinamide were 3.3 mg/L, 6.5 mg/L, and 30.9 mg/L, respectively, all of which much exceed the minimum inhibitory concentration (MIC) for Mycobacterium tuberculosis. Peritoneal fluid concentrations of isoniazid and pyrazinamide were maintained well above the MICs for M. tuberculosis; however, peritoneal fluid concentration of rifampin was below the therapeutic range most of the time.
♦ Conclusion
For the treatment of systemic or pulmonary tuberculosis in CAPD patients, no dose adjustments are required for isoniazid, rifampin, or pyrazinamide. On the contrary, for the treatment of tuberculous peritonitis, oral rifampin therapy is not expected to be effective because of its low peritoneal fluid concentration.
LuiSL, LoCY, ChoyBY, ChanTM, LoWK, ChengIK. Optimal treatment and long-term outcome of tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis1996; 28:747–51.
6.
ChengIK, ChanPC, ChanMK. Tuberculous peritonitis complicating long-term peritoneal dialysis. Report of 5 cases and review of the literature. Am J Nephrol1989; 9:155–61.
7.
AhijadoF, LunoJ, SotoI, GallegoE, JuncoE, PoloJR. Tuberculous peritonitis in patients on CAPD. Contrib Nephrol1991; 89:79–86.
8.
HwangYS, AhnJH, LeeTW, IhmCG, KimMJ. 3 cases of tuberculous peritonitis complicating long term CAPD. Korean Journal of Nephrology1991; 10:245–9.
9.
LeeWK, ParkSB, KimHC. Tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Korean Journal of Nephrology1990; 9:90–5.
10.
WooJ, LeungA, ChanK, LaiKN, TeohR. Pyrazinamide and rifampicin regimens for patients on maintenance dialysis. Int J Artif Organs1988; 11:181–5.
11.
OlsonWA, DaytonPG, IsrailiZH, PruittAW. Spectrophotofluorometric assay for isoniazid and acetylisoniazid in plasma adapted to pediatric studies. Clin Chem1977; 23:745–8.
12.
JamaluddinABM, SarwarG, RahimMA, RahmanMK. High-performance liquid chromatographic assay of rifampicin in human serum. J Chromatogr1990; 525: 495–7.
13.
YamamotoT, MoriwakiY, TakahashiS, HadaT, HigashinoK. Rapid and simultaneous determination of pyrazinamide and its major metabolites in human plasma by high-performance liquid chromatography. J Chromatogr1987; 413:342–6.
14.
EllardGA. Chemotherapy of tuberculosis for patients with renal impairment. Nephron1993; 64:169–81.
15.
KimDJ, KimSK, LeeJS, HanYC, LeeMH, LeeSH. Pharmacokinetic changes of pyrazinamide in patients with impaired renal function during hemodialysis. Korean J Intern Med1986; 31:13–19.
16.
HoldinessMR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet1985; 10:532–4.
17.
EllardGA. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle1969; 50:144–58.
18.
Hong Kong Tuberculosis Treatment Services/British Medical Research Council. Adverse reactions to short course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle1976; 57:81–95.
19.
StamatakisG, MontesC, TrouvinJH, FarinottiR, FessiH, KenouchS. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. Clin Nephrol1988; 30:230–4.
20.
LacroixC, HoangTP, NouveauJ, GuyonnaudC, LaineG, DuwoosH. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol1989; 36:395–400.
21.
AndrewOT, SchoenfeldPY, HopewellPC, HumphreysMH. Tuberculosis in patients with end-stage renal disease. Am J Med1980; 68:59–65.
22.
McEvoyGK. AHFS Drug Information. Bethesda, MD: the American Society of Health-System Pharmacists, Inc; 2001.
23.
PaivaA, CirugedaA, BajoMA, SelgasR. Successful treatment of peritonitis in CAPD with intraperitoneal rifampin. Perit Dial Int1998; 18:543–4.
